Basic Pathologic Processes of the Heart

Relationship to Cardiomyopathies
  • L. Maximilian Buja
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 34)


Cardiomyopathy is broadly defined as heart muscle disease. This chapter reviews certain basic pathologic processes affecting the heart and discusses the relationship of these processes to various cardiomyopathies. Additional information regarding several of these pathologic processes is provided in other chapters of this book.


Cardiac Hypertrophy Hypertrophic Cardiomyopathy Constrictive Pericarditis Viral Myocarditis Coronary Spasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hillis LD, Braunwald E: Myocardial ischemia. N Engl J Med 296:971–978, 1034–1041, 1093–1096, 1977.Google Scholar
  2. 2.
    Willerson JT, Hillis LD, Buja LM: Pathogenesis and pathology of ischemic heart disease. In: Ischemic heart disease: clinical and pathophysiological aspects. New York: Raven, 1982.Google Scholar
  3. 3.
    Willerson JT, Buja LM: Cause and course of acute myocardial infarction. Am J Med 69: 903–914, 1980.PubMedCrossRefGoogle Scholar
  4. 4.
    Buja LM, Willerson JT: Clinicopathologic findings in acute ischemic heart disease syndromes. Am J Cardiol 47: 343–356, 1981.PubMedCrossRefGoogle Scholar
  5. 5.
    Oliva PB: Pathophysiology of acute myocardial infarction, 1981. Ann Intern Med 94: 236–250, 1981.PubMedCrossRefGoogle Scholar
  6. 6.
    Buja LM, Hillis LD, Petty CS, Willerson JT: The role of coronary arterial spasm in ischemic heart dis ease. Arch Pathol Lab Med 105: 221–226, 1981.PubMedGoogle Scholar
  7. 7.
    Hirsh PD, Campbell WB, Willerson JT, Hillis LD:Prostaglandins and ischemic heart disease. Am J Med 71: 1009–1026, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Reimer KA, Jennings RB: The “wavefront phenomenon” of myocardial ischemic cell death. II. Trans-mural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40: 633–644, 1979.Google Scholar
  9. 9.
    Willerson JT, Parkey RW, Bonte FJ, Lewis SE, Corbett J, Buja LM: Pathophysiologic considerations and clinicopathological correlates of technetium-99m stannous pyrophosphate myocardial scintigraphy. Semin Nucl Med 10: 54–69, 1980.Google Scholar
  10. 10.
    Hagler H, Burton K, Buja L: Electron probe x-ray microanalysis of normal and injured myocardium: methods and results. In: Hutchinson TE, Somlyo AP (eds), Microprobe analysis of biological systems. New York: Academic, 1981, pp 245–281.Google Scholar
  11. 11.
    Schlesinger MJ, Reiner L: Focal myocytolysis of the heart. Am J Pathol 31: 443–459, 1955.Google Scholar
  12. 12.
    Buja LM, Willerson JT: Abnormalities of volume regulation and membrane integrity in myocardial tissue slices after early ischemic injury in the dog: effects of mannitol, polyethylene glycol and propranolol. Am J Pathol 103: 79–95, 1981.Google Scholar
  13. 13.
    Burton, KP, Hagler HK, Willerson JT, Buja LM: Relationship of abnormal intracellular lanthanum accumulation to progression of ischemic injury in isolated perfused myocardium: effect of chlorpromazine. Am J Physiol 241: H714 - H723, 1981.Google Scholar
  14. 14.
    Chien KR, Reeves JP, Buja LM, Bonte F, Parkey RW, Willerson JT: Phospholipid alterations in canine ischemic myocardium: temporal and topographical correlations with Tc-99m-PPi accumulation and an in vitro sarcolemmal Cat+ permeability defect. Circ Res 48: 711–719, 1981.Google Scholar
  15. 15.
    Mukherjee A, Bush LR, McCoy KE, Duke RJ, Hagler H, Buja LM, Willerson JT: Relationship between 13-adrenergic receptor numbers and physiological responses during experimental canine myocardial ischemia. Circ Res 50: 735–741, 1982.Google Scholar
  16. 16.
    Corr PB, Shayman JA, Kramer JB, Kipnis RJ: Increased alpha adrenergic receptors in ischemic cat myocardium: a potential mediator of electrophysiological derangements. J Clin Invest 67: 1232–1236, 1981.Google Scholar
  17. 17.
    Muntz KH, Hagler HK, Boulos HJ, Willerson JT, Buja LM: Redistribution of catecholamines in the ischemic zone of the dog heart. Am J Path 114: 6478, 1984.Google Scholar
  18. 18.
    Reichenbach DD, Benditt EP: Catecholamines and cardiomyopathy: the pathogenesis and potential importance of myofibrillar degeneration. Hum Pathol 1: 125–150, 1970.Google Scholar
  19. 19.
    Buja LM, Ferrans VJ, Roberts WC: Drug-induced cardiomyopathies. In: Homburger F (ed) Comparative pathology of the heart. Advances in cardiology, vol 13. Basel: Karger, 1974, pp 330–348.Google Scholar
  20. 20.
    Buja LM, Ferrans VJ: Myocardial injury produced by antineoplastic drugs. In: Fleckenstein A, Rona G (eds) Pathophysiology and morphology of myocardial cell alteration. Recent advances in studies on cardiac structure and metabolism, vol 6. Baltimore: University Park, 1975, pp 487–497.Google Scholar
  21. 21.
    Rubin E: Alcohol: toxic or tonic? Cardiovasc Rev Rep 2: 23–29, 1981.Google Scholar
  22. 22.
    Csap6 Z, Dusek J, Rona G: Early alterations of the cardiac muscle cells in isoproterenol-induced necrosis. Arch Pathol 93: 356–365, 1972.Google Scholar
  23. 23.
    Rona G, Boutet M, Hüttner I, Peters H: Pathogenesis of isoproterenol-induced myocardial alterations: functional and morphological correlates. In: Dhalla NS (ed) Myocardial metabolism. Recent advances in studies on cardiac structure and metabolism, vol 3. Baltimore: University Park, 1973, pp 507–525.Google Scholar
  24. 24.
    Ferrans VJ: Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62: 995–961, 1978.Google Scholar
  25. 25.
    Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 305: 139–153, 1981.PubMedCrossRefGoogle Scholar
  26. 26.
    Olson RD, Boerth RC, Gerber JG, Nies AS: Mechanisms of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29: 1393–1401, 1981.PubMedCrossRefGoogle Scholar
  27. 27.
    Dalbow DG, Jaenke RS: In vivo RNA synthesis in the hearts of adriamycin-treated rats. Cancer Res 42: 79–83, 1982.PubMedGoogle Scholar
  28. 28.
    Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR: Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances. Lab Invest 45: 157–168, 1981.PubMedGoogle Scholar
  29. 29.
    Lerner AM, Wilson FM: Virus myocardiopathy. Prog Med Virol 15: 63–91, 1973.PubMedGoogle Scholar
  30. 30.
    Abelman WH: Viral myocarditis and its sequelae. Annu Rev Med 22: 145–152, 1973.CrossRefGoogle Scholar
  31. 31.
    Woodruff JF: Viral myocarditis: a review. Am J Pathol 101: 425–484, 1980.PubMedGoogle Scholar
  32. 32.
    Cambridge G, MacArthur CGC, Waterson AP, Goodwin JF, Oakley CM: Antibodies to Coxsackie B viruses in congestive cardiomyopathy. Br Heart J 41: 692–696, 1979.PubMedCrossRefGoogle Scholar
  33. 33.
    Kirsner AB, Hess EV, Fowler NO: Immunologic findings in idiopathic cardiomyopathy: a prospective serial study. Am Heart J 86: 625–630, 1973.PubMedCrossRefGoogle Scholar
  34. 34.
    Bolte HD, Schultheiss P: Immunological results in myocardial diseases. Postgrad Med J 54: 500–503, 1978.PubMedCrossRefGoogle Scholar
  35. 35.
    Jacobs B, Matsuda Y, Deodhar S, Shirey E: Cell-mediated cytotoxicity to cardiac cells of lymphocytes from patients with primary myocardial disease. Am J Clin Pathol 72: 1–4, 1979.PubMedGoogle Scholar
  36. 36.
    Fowles RE, Dieber CP, Stinson EB: Defective in vitro suppressor cell function in idiopathic congestive cardiomyopathy. Circulation 59: 483–491, 1979.PubMedCrossRefGoogle Scholar
  37. 37.
    Hang LM, Izui S, Dixon FJ: (NZW X BXSB) F, hybrid: a model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med 154: 216–221, 1981.PubMedCrossRefGoogle Scholar
  38. 38.
    Meerson FZ: The myocardium in hyperfunction, hy pertrophy and heart failure. Circ Res (Suppl 2) 24 and 25:II-1–163, 1969.Google Scholar
  39. 39.
    Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol 5: 370–382, 1960.PubMedCrossRefGoogle Scholar
  40. 40.
    Hort W: Quantitative morphology and structural dynamics of the myocardium. In: Bajusz E, Jasmin G (eds) Methods and achievements in experimental pathology, vol 5. Basel: Karger, 1971, pp 3–21.Google Scholar
  41. 41.
    Bishop SP, Hine P: Cardiac muscle cytoplasmic and nuclear development during canine neonatal growth. In: Roy P-E, Harris P (eds) The cardiac sarcoplasm. Recent advances in studies on cardiac structure and metabolism, vol 8. Baltimore: University Park, 1975, pp 77–98.Google Scholar
  42. 42.
    Grossman W: Cardiac hypertrophy: useful adaptation or pathologic process? Am J Med 69: 576–584, 1980.PubMedCrossRefGoogle Scholar
  43. 43.
    Wikman-Coffelt J, Parmley WW, Mason DR: The cardiac hypertrophy process: analysis of factors determining pathological vs. physiological development. Circ Res 45: 697–707, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Rabinowitz M, Zak R: Biochemical and cellular changes in cardiac hypertrophy. Annu Rev Med 23: 245–262, 1972.PubMedCrossRefGoogle Scholar
  45. 45.
    Morkin E: Activation of synthetic processes in cardiac hypertrophy. Circ Res (Suppl 2) 34 and 35: II-37–48, 1974.Google Scholar
  46. 46.
    Cohen J: Role of endocrine factors in the pathogenesis of cardiac hypertrophy. Circ Res (Suppl 2) 34 and 35: II-49–57, 1974.Google Scholar
  47. 47.
    Schreiber SS, Evans CD, Oratz M, Rothschild MA: Protein synthesis and degradation in cardiac stress. Circ Res 48: 601–611, 1981.PubMedCrossRefGoogle Scholar
  48. 48.
    Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56: 56–64, 1975.PubMedCrossRefGoogle Scholar
  49. 49.
    Buja LM, Muntz KH, Lipscomb K, Willerson JT: Cardiac hypertrophy in chronic ischemic heart disease. In: Tarazi R (ed) Mechanisms of left ventricular hypertrophy. New York: Raven, 1983 (in press).Google Scholar
  50. 50.
    Braunwald E, Ross J Jr, Sonnenblick EH: Mechanisms of contraction of the normal and failing heart, 2nd edn. Boston: Little, Brown and Company, 1976.Google Scholar
  51. 51.
    Braunwald E: Historical overview and pathophysiologic considerations. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 3–9.Google Scholar
  52. 52.
    Schwartz A, Sordahl LA, Entman ML, Allen JC, Reddy YS, Goldstein MA, Luchi RJ, Wyborny LE: Abnormal biochemistry in myocardial failure. Am J Cardiol 32: 407–422, 1973.PubMedCrossRefGoogle Scholar
  53. 53.
    Dhalla NS, Das PK, Sharma GP: Subcellular basis of cardiac contractile failure. J Mol Cell Cardiol 10: 363–385, 1978.PubMedCrossRefGoogle Scholar
  54. 54.
    Chidsey CA: Calcium metabolism in the normal and failing heart. In: The myocardium: failure and infarction. New York: HP Publishing, 1975, pp 37–47.Google Scholar
  55. 55.
    Willerson JT: What is wrong with the failing heart? N Engl J Med 307: 243–245, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Sonneblick EH, Factor S, Strobeck JE, Capasso JM, Fein F: The pathophysiology of heart failure: the primary role of microvascular hyperactivity and spasm in the development of congestive cardiomyopathies. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 87–97.Google Scholar
  57. 57.
    Sole MJ: Alterations in sympathetic and parasympathetic neurotransmitter activity. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 101–113.Google Scholar
  58. 58.
    Bristow MR, Ginsbury R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham M, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and (3-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205–211, 1982.PubMedCrossRefGoogle Scholar
  59. 59.
    Buja LM, Petty CS: Heart disease, trauma, and death. In: Curran WJ, McGarry AL, Petty CS (eds) Modern legal medicine, psychiatry, and forensic science. Philadelphia: FA Davis, 1980, pp 187–206.Google Scholar
  60. 60.
    Yoran C, Covell JW, Ross J Jr: Structural basis for the ascending limb of left ventricular function. Circ Res 32: 297–303, 1973.PubMedCrossRefGoogle Scholar
  61. 61.
    Mayon BJ, Ferrans VJ: Ultrastructural features of hypertrophied human ventricular myocardium. Prog Cardiovasc Dis 11: 207–238, 1978.Google Scholar
  62. 62.
    Dick MR, Unverferth DV, Baba N: The pattern of myocardial degeneration in nonischemic congestive cardiomyopathy. Hum Pathol 13: 740–744, 1982.PubMedCrossRefGoogle Scholar
  63. 63.
    Tarazi RC, Sen S, Fouad FM: Regression of myocardial hypertrophy. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 151–163.Google Scholar
  64. 64.
    Wynne J, Braunwald E: The cardiomyopathies and myocardities. In: Braunwald E (ed) Heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders, 1980, pp 1437–1498.Google Scholar
  65. 65.
    Goodwin JF: Congestive and hypertrophie cardiomyopathies: a decade of study. Lancet 1: 731–739, 1970.CrossRefGoogle Scholar
  66. 66.
    Roberts WC, Ferrans VJ: Pathologic anatomy of the cardiomyopathies: idiopathic dilated and hypertrophie types, infiltrative types, and endomyocardial disease with and without eosinophilia. Hum Pathol 6: 287–342, 1975.PubMedCrossRefGoogle Scholar
  67. 67.
    Clark CE, Henry WL, Epstein SE: Familial prevalence and genetic transmission of idiopathic hypertrophie subaortic stenosis. N Engl J Med 289: 709714, 1973.Google Scholar
  68. 68.
    Goodwin JF: ?IHSS. ?HOCM. ?ASH. a plea for unity. Am Heart J 89:269–277, 1975.Google Scholar
  69. 69.
    Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE: Sudden death in young athletes. Circulation 62: 218–229, 1980.PubMedCrossRefGoogle Scholar
  70. 70.
    Maron BJ, Roberts WC: Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophie cardiomyopathy. Circulation 59: 689–706, 1979.PubMedCrossRefGoogle Scholar
  71. 71.
    Buja LM, Khoi NB, Roberts WC: Clinically significant cardiac amyloidosis: clinicopathologic findings in 15 patients. Am J Cardiol 26: 394–405, 1970.PubMedCrossRefGoogle Scholar
  72. 72.
    Cutler DJ, Isner JM, Bracey AW, Hufnagel CA, Conrad PW, Roberts WC, Kerwin DM, Weintraub AM: Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathy. Am J Med 69: 923–928, 1980.PubMedCrossRefGoogle Scholar
  73. 73.
    Billingham ME, Bristow MR, Mason JW, Joseph LJ: Endomyocardial biopsy. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 237–251.Google Scholar
  74. 74.
    Nippoldt TB, Edwards WD, Holmes DR Jr, Reeder GS, Hartzler GO, Smith HC: Right ventricular endomyocardial biopsy: clinicopathologic correlates in 100 consecutive patients. Mayo Clin Proc 57: 407418, 1982.Google Scholar
  75. 75.
    Mason JW, Bilingham ME, Ricci DR: Treatment of acute inflammatory myocarditis by endomyocardial biopsy. Am J Cardiol 45: 1037–1044, 1980.PubMedCrossRefGoogle Scholar
  76. 76.
    O’Connell JB, Robinson JA, Henkin RE, Gunnar RM: Immunosuppressive therapy in patients with congestive cardiomyopathy and myocardial uptake of gallium-67. Circulation 64: 780–786, 1981.PubMedCrossRefGoogle Scholar
  77. 77.
    Bishop SP: Animal models. In: Braunwald E, Mock MB, Watson J (eds) Congestive heart failure: current research and clinical applications. New York: Grune and Stratton, 1982, pp 125–149.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • L. Maximilian Buja

There are no affiliations available

Personalised recommendations